Exelixis, Inc. 10-Q Summary: Period Ended June 30, 2000
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Exelixis, Inc., a model system genetics and comparative genomics company, for the period ended June 30, 2000. The company operates in a single segment in the United States, focusing on identifying critical genes in disease pathways for pharmaceutical and agricultural applications. As of July 31, 2000, there were 44,948,329 shares of common stock outstanding.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2000 | Six Months Ended June 30, 1999 |
|---|---|---|
| Total Revenues | $11,567,000 | $3,575,000 |
| Net Loss | ($18,260,000) | ($7,055,000) |
| Net Loss Per Share (Basic/Diluted) | ($0.90) | ($2.04) |
| Cash and Cash Equivalents (End of Period) | $51,418,000 | $11,190,000 |
| Short-Term Investments | $74,621,000 | $1,504,000 |
| Total Liquidity (Cash + ST Investments) | $126,039,000 | $12,694,000 |
| Operating Cash Flow | $3,426,000 | ($1,758,000) |
| Accumulated Deficit | ($72,987,000) | ($54,727,000) |
Debt and Liabilities: Total liabilities were $33,755,000. This includes a $7,500,000 convertible promissory note to Pharmacia Corporation (converted to common stock in July 2000), $2,496,000 in notes payable, and $14,820,000 in deferred revenue.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 224% year-over-year (from $3.6M to $11.6M for the six-month period), driven by license and contract revenues from collaborations with Bayer, Pharmacia, and Bristol-Myers Squibb.
- Expense Expansion: Operating expenses increased 194% (from $10.7M to $31.5M). Research and Development (R&D) expenses rose 206% to $22.3M, and General and Administrative (G&A) expenses rose 170% to $9.2M.
- Stock Compensation: Non-cash stock compensation expense was a significant driver of increased expenses, totaling $8.6M for the six months ended June 30, 2000, compared to $0.8M in the prior year period.
- Liquidity Transformation: The company completed an Initial Public Offering (IPO) in April 2000, raising approximately $124.7 million in net proceeds. This transformed the balance sheet from a deficit position to a strong cash position of over $126 million.
- Operating Cash Flow: Shifted from a cash burn of $1.8M in the prior year to a positive cash flow of $3.4M, primarily due to an increase in deferred revenue from collaborators.
Guidance, Outlook, and Risks
Outlook: Management expects to continue incurring net losses and negative cash flow for the foreseeable future due to planned R&D expenditures. The company believes current cash, investments, and collaborator funding will satisfy needs for at least the next two years, though additional financing may be sought.
Key Risks:
- Profitability: No history of profitability; significant additional revenue is required to offset rising operating expenses.
- Collaboration Dependence: Substantially all revenues are derived from collaborations with major companies (Bayer, Pharmacia, Bristol-Myers Squibb, Dow AgroSciences). Termination or failure to achieve milestones in these agreements would severely impact revenue.
- Capital Needs: Future capital requirements are substantial. Failure to raise additional capital could force curtailment of operations.
- Regulatory and Market: Products are subject to lengthy regulatory approval processes. Public acceptance of genetically engineered products remains uncertain.
- Stock Volatility: The stock price is expected to be highly volatile following the IPO.
Investor Verification Checklist
- Collaboration Milestones: Verify the status of revenue recognition triggers and milestone payments with Bayer, Pharmacia, Bristol-Myers Squibb, and Dow AgroSciences.
- Stock Compensation Impact: Assess the sustainability of operating margins given the high non-cash stock compensation expense ($8.6M in six months) and future vesting schedules.
- Cash Burn Rate: Monitor the rate of cash consumption against the $126M liquidity position to validate the "two-year runway" assertion.
- Convertible Note Conversion: Confirm the final terms and share count impact of the $7.5M Pharmacia note conversion completed in July 2000.
- Lease Commitments: Review the $32.0 million future lease commitment for the new South San Francisco facility and its impact on future fixed costs.